| Print
Atossa Therapeutics (ATOS)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Address
107 Spring Street
Seattle
WA
USA
98104
Telephone
+1 206 5880256
Forecast key dates
| Name | Key Date |
|---|---|
| Atossa Therapeutics Inc Third Quarter Earnings Results for 2026 | 2026-11-12T00:00:00 |
| Atossa Therapeutics Inc Second Quarter Earnings Results for 2026 | 2026-08-12T00:00:00 |
| Atossa Therapeutics Inc First Quarter Earnings Results for 2026 | 2026-05-13T00:00:00 |
| Atossa Therapeutics Inc Annual General Meeting for 2026 | 2026-05-08T06:00:00 |
| Atossa Therapeutics Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-03-25T08:30:00 |
| Atossa Therapeutics Inc Fourth Quarter Earnings Results for 2025 | 2026-03-25T00:00:00 |
| Atossa Therapeutics Inc Annual Report for 2025 | 2026-03-25T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Atossa Therapeutics Inc Third Quarter Earnings Results for 2025 | 2025-11-12T00:00:00 |
| 27th Annual H.C. Wainwright Global Investment Conference | 2025-09-08T15:00:00 |
| Atossa Therapeutics Inc Second Quarter Earnings Results for 2025 | 2025-08-12T00:00:00 |
| Jefferies Global Healthcare Conference | 2025-06-05T07:35:00 |
| Atossa Therapeutics Inc First Quarter Earnings Results for 2025 | 2025-05-13T00:00:00 |
| Atossa Therapeutics Inc Annual General Meeting for 2025 | 2025-05-08T06:00:00 |
| Atossa Therapeutics Inc Fourth Quarter Earnings Conference Call for 2024 | 2025-03-25T08:30:00 |
| Atossa Therapeutics Inc Fourth Quarter Earnings Result for 2024 | 2025-03-25T00:00:00 |
| Atossa Therapeutics Inc Annual Report for 2024 | 2025-03-25T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.